<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322617</url>
  </required_header>
  <id_info>
    <org_study_id>ATHENA</org_study_id>
    <nct_id>NCT04322617</nct_id>
  </id_info>
  <brief_title>Anlotinib Plus PD-1 Antibody in Standard Chemotherapy Failure Advanced NSCLC： the ATHENA Study</brief_title>
  <acronym>ATHENA</acronym>
  <official_title>Anlotinib Plus PD-1 Antibody in Standard Chemotherapy Failure Advanced Non-small Cell Lung Cancer (Athena Study）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the efficacy and safety of Anlotinib plus PD-1 antibody in
      Standard Chemotherapy Failure Advanced Non-small Cell Lung Cancer (Athena study）
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to explore the efficacy and safety of Anlotinib plus PD-1 antibody in
      Standard Chemotherapy Failure Advanced Non-small Cell Lung Cancer. We aim to enrolled 100
      patients in this study, the primary endpoint was PFS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">March 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>may 2020- may 2021 (1 year)</time_frame>
    <description>Progression free survival time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>may 2020- may 2021 (1 year)</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>may 2020- may 2021 (1 year)</time_frame>
    <description>Over survival time</description>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue sample and plasma DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Standard Chemotherapy Failure Advanced NSCLC
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology

          -  Standard Chemotherapy Failure

          -  Treatment Plan is Anlotinib Plus PD-1 Antibody

        Exclusion Criteria:

          -  Patients with contraindication of chemotherapy

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongchang Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongchang Zhang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>+861383123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yongchang Zhang</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+8613873123436</phone>
      <phone_ext>+8613873123436</phone_ext>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>anlotinib, PD-1 antibody, NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

